Brain Advance Access published online on September 12, 2008
Brain, doi:10.1093/brain/awn220
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
PET imaging of brain 5-HT1A receptors in the preoperative evaluation of temporal lobe epilepsy
1Hospices Civils de Lyon, Service de Neurologie Fonctionnelle et d’Épileptologie, Hôpital Pierre Wertheimer, Boulevard Pinel, Lyon F-69003, 2Université Lyon 1, Lyon F-69003, 3INSERM, U879, Lyon F-69003, 4Institut Fédératif des Neurosciences de Lyon, Lyon F-69003, 5CERMEP, Lyon F-69003, 6INSERM U821, 7CTRS-INSERM IDEE, Lyon F-69003, 8INSERM U642, Rennes F-35042, 9Université de Rennes 1, LTSI, Rennes F-35042, France and 10MRC Clinical Sciences Centre and Division of Neuroscience, Faculty of Medicine, Imperial College, Hammersmith Hospital, DuCane Road, London, UK
Correspondence to:
François Mauguière, Functional Neurology and Epilepsy Department, Hôpital Pierre Wertheimer, 59, Boulevard Pinel, Lyon F-69003, France E-mail: mauguiere{at}univ-lyon1.fr
[18F]MPPF PET has previously been used to identify the epileptic lobe in temporal lobe epilepsy (TLE) patients at the group level. This study aims to validate the visual analysis of [18F]MPPF PET in the assessment of individual TLE patients for their suitability to undergo temporal lobe resection. Forty-two patients suffering from TLE and 18 control subjects matched for age and gender were prospectively enrolled for [18F]MPPF PET. Four subtypes were defined according to the presurgical evaluation: mesio-TLE (MTLE, 32 patients), temporal neocortical epilepsy (NC, five patients), temporo-perisylvian epilepsy (T+, three patients) and temporal epilepsy without further information (t, two patients). Parametric binding potential (BPND) images were obtained using a simplified reference tissue model. Three examiners, who were blinded to other data, visually interpreted each scan and delineated areas of decreased [18F]MPPF BPND. Statistical parametric mapping (SPM) analysis of MPPF BPND images was also performed. Visual analysis showed a low rate of disagreement between the three examiners (7%). PET scans were considered normal in four patients (9.5%). In the remaining 38 patients (90.5%), areas of focal BPND decrease were identified. A specific pattern was encountered in the MTLE subgroup, consisting of a BPND decrease involving hippocampus, amygdala and temporal pole altogether. Combining the results from the presurgical investigations and the surgical outcome, we estimated that the area of BPND decrease coincided with the epileptogenic zone in 40% of patients in the MTLE subgroup and 33% in the other TLE subtypes. This relatively low precision was due to 47% of patients who showed BPND decreases in the insula ipsilateral to the epileptogenic lobe. The SPM analysis had much lower sensitivity (67%) to detect BPND decreases in the epileptogenic temporal lobe, but revealed areas of increased BPND outside the epileptogenic zone and bitemporal BPND decreases of undetermined clinical significance, which were undetectable by visual analysis, in 29% of patients. In conclusion, visual analysis of [18F]MPPF BPND images helps in the correct identification of the epileptogenic temporal lobe in all patients showing BPND decreases, with a false negative rate inferior to 10% and no false positives in control subjects. All TLE patients with [18F]MPPF BPND decreases involving hippocampus, amygdala and temporal pole together, with or without extension to the ipsilateral insula, were good candidates for anterior temporal lobectomy. All these patients became seizure free after surgery, even when the clinical presentation was not that of a typical MTLE, or when MRI failed to detect hippocampal atrophy.
Key Words: temporal lobe epilepsy; brain 5-HT1A receptors; serotonin; [18F]MPPF PET; presurgical evaluation
Abbreviations: BPND, binding potential; EZ, epileptogenic zone; FDG, [18F]deoxyglucose; MTLE, mesio-temporal lobe epilepsy; NC, Temporal neocortex; SPM, Statistical parametric mapping; TLE, temporal lobe epilepsy; PVE, Partial volume effect; 5-HT1A, 5-hydroxytryptamine-1A
Received April 3, 2008. Revised June 25, 2008. Accepted August 21, 2008.